fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15   |   16      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-02-19 Vivalis (France)
Kyoto Biken (Japan)
EB66® cell line for the production of viral vaccines licensing
See details
2010-02-18 Swedish Orphan Biovitrum (Sweden)
BiogenIdec (USA)
recombinant Factor VIII Fc fusion protein (rFVIIIFc)
recombinant Factor IX Fc fusion protein (rFIXFc) / Hemophilia A and B
R&D
licensing
commercialization/ distribution
development
marketing/ promotion
other
See details
2010-02-18 Galapagos (Belgium)
Morphosys (Germany)
antibody therapeutics / bone & joint diseases, including rheumatoid arthritis, osteoporosis and osteoarthritis R&D
development
See details
2010-02-17 Roche Molecular Systems (Switzerland-USA)
Merck & Co (USA)
AmpliChip p53 Test / cancers harboring a dysfunctional p53 gene R&D
licensing
other
See details
2010-02-17 Aureus-Pharma (France)
Sanofi-Aventis (France)
DDI Predict 2009 Edition (risk analysis of potential drug-drug interactions) R&D
other
See details
2010-02-16 Rigel Pharmaceuticals (USA)
AstraZeneca (UK)
fostamatinib disodium (R788)
(oral Spleen Tyrosine Kinase (Syk) inhibitor) / rheumatoid arthritis and additional indications
commercialization/ distribution
development
See details
2010-02-16 Philogen (Italy)
Bayer HealthCare Manufacturing (Germany)
  manufacturing
See details
2010-02-16 immatics biotechnologies (Germany)
Cancer Research UK (UK)
therapeutic cancer vaccine IMA950

It consists of 11 tumour-associated peptides (TUMAPs) which the immatics platform selects on the basis of their natural presentation by tumour tissue, immunogenicity and their relevance to tumour function. / glioblastoma
other
See details
2010-02-09 Debiopharm (Switzerland)
Novartis (Switzerland)
Debio 025 (alisporivir - synthetic first-in-class cyclophilin inhibitor) / hepatitis C licensing
commercialization/ distribution
development
marketing/ promotion
See details
2010-02-08 Active Biotech (Sweden)
Teva Pharmaceutical Industries (Israel)
laquinimod / relapsing-remitting multiple sclerosis commercialization/ distribution
marketing/ promotion
See details
2010-02-08 Johns Hopkins University (USA)
Qiagen (The Netherlands)
biomarker PI3K / cancer licensing
See details
2010-02-05 Therapure Biopharma (Canada)
LFB Biomedicaments (France)
undisclosed plasma proteins including coagulation factors manufacturing
See details
2010-02-05 DxS, subsidiary of Qiagen (The Netherlands)
Pfizer (USA)
companion diagnostic test kit for the immunotherapy vaccine PF-04948568 (CDX-110).
PF-04948568 is a 14 amino acid peptide chemically conjugated to Keyhole Limpet Hemocyanin (KLH). It is targeting the tumor specific epidermal growth factor receptor (EGFR) mutant EGFRvIII.
On April 16, 2008, Pfizer Vaccines LLC. has been granted an exclusive worldwide license to the product. A phase II study is ongoing in patients with glioblastoma multiforme (ACT III) (See clintrials.gov). / glioblastoma multiforme
licensing
development
See details
2010-02-04 Ariana Pharma (France)
Fovea Pharmaceuticals (France)
services (Phase II clinical data analysis using KEM® (Knowledge Extraction and Management) decision support platform ) other
See details
2010-02-04 Massachusetts General Hospital (USA)
Harvard University (USA)
Roche (Switzerland)
cellular models of disease based on human stem cell lines / metabolic disorders and cardiovascular diseases R&D
other
See details
[<<]      «      6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15   |   16      »      [65]